(Q77078715)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

title

Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

author name string

M Tabone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

C Laudi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

B Delmastro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

A Biglino

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

F Chieppa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

R Bonardi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

G Cariti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

S Cusumano

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

F Brunello

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

G Calleri

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

A Manca

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

P Della Monica

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

L Sidoli

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

M Rizzetto

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

A Pera

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

publication date

1 October 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

page(s)

517-521

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

Interferon for non-A, non-B chronic hepatitis

2 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

Clinical pharmacokinetics of amantadine hydrochloride.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

Treatment of chronic hepatitis C with amantadine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

Inhibition of uncoating of fowl plague virus by l-adamantanamine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

On the Mechanism of Inhibition of Influenza Virus Replication by Amantadine Hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900166-0

7 January 2021

10.1016/S0168-8278(01)00166-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11682037%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference